Spots Global Cancer Trial Database for Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
Official Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Study ID: NCT06151197
Study Description
Brief Summary: This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Endo Site 11, Tucson, Arizona, United States
Endo Clinical Site 2, Encinitas, California, United States
Endo Site 8, Fresno, California, United States
Endo Site 9, Los Angeles, California, United States
Endo Site 17, Westminster, Colorado, United States
Endo Clinical Site 1, Pinellas Park, Florida, United States
Endo Site 14, Plantation, Florida, United States
Endo Site 5, Pasadena, Maryland, United States
Endo Site 16, Grand Rapids, Michigan, United States
Endo Site 12, Jefferson City, Missouri, United States
Endo Site 15, Durham, North Carolina, United States
Endo Site 10, Altoona, Pennsylvania, United States
Endo Site 3, Bedford, Texas, United States
Endo Site 7, Georgetown, Texas, United States
Endo Site 4, McAllen, Texas, United States
Endo Site 6, Salt Lake City, Utah, United States
Endo Site 13, Suffolk, Virginia, United States
Contact Details
Name: Luis Ortega
Affiliation: Endo Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
